LON:VRP - Verona Pharma Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
GBX 54.50 +1.00 (+1.87 %)
(As of 02/22/2019 07:19 AM ET)
Previous CloseGBX 53.50
Today's RangeGBX 52.10 - GBX 54.50
52-Week RangeGBX 100 - GBX 189
Volume9,677 shs
Average Volume49,797 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and IIa clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease and cystic fibrosis. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.

Receive VRP News and Ratings via Email

Sign-up to receive the latest news and ratings for VRP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology



Sales & Book Value

Annual SalesN/A



Next Earnings DateN/A

Verona Pharma (LON:VRP) Frequently Asked Questions

What is Verona Pharma's stock symbol?

Verona Pharma trades on the London Stock Exchange (LON) under the ticker symbol "VRP."

How were Verona Pharma's earnings last quarter?

Verona Pharma Plc (LON:VRP) posted its earnings results on Tuesday, May, 8th. The company reported ($14.50) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($23.70) by $9.20. View Verona Pharma's Earnings History.

What price target have analysts set for VRP?

3 brokerages have issued twelve-month price targets for Verona Pharma's stock. Their forecasts range from GBX 160 to GBX 348. On average, they expect Verona Pharma's stock price to reach GBX 254 in the next twelve months. This suggests a possible upside of 366.1% from the stock's current price. View Analyst Price Targets for Verona Pharma.

What is the consensus analysts' recommendation for Verona Pharma?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verona Pharma in the last year. There are currently 2 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Verona Pharma.

Has Verona Pharma been receiving favorable news coverage?

Headlines about VRP stock have trended very negative recently, InfoTrie Sentiment reports. The research firm identifies positive and negative press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Verona Pharma earned a daily sentiment score of -3.0 on InfoTrie's scale. They also gave media stories about the company a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the stock's share price in the next several days.

Who are some of Verona Pharma's key competitors?

What other stocks do shareholders of Verona Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Verona Pharma investors own include Fate Therapeutics (FATE), Pluristem Therapeutics (PSTI), GRIFOLS S A/S (GRFS), Lexicon Pharmaceuticals (LXRX), Amicus Therapeutics (FOLD), AbbVie (ABBV), Shire (SHPG), Exelixis (EXEL), Madalena Energy (MVN) and Global Blood Therapeutics (GBT).

Who are Verona Pharma's key executives?

Verona Pharma's management team includes the folowing people:
  • Dr. Jan-Anders Karlsson, CEO & Exec. Director (Age 64)
  • Mr. Piers John Morgan MA, ACA, Chief Financial Officer (Age 53)
  • Ms. Claire Louise Poll B.A., B Juris, LLB, ASIA, Gen. Counsel (Age 52)
  • Dr. Peter Spargo, Sr. VP of Chemistry Manufacturing & Controls (Age 57)
  • Mr. Richard Hennings, Commercial Director (Age 49)

How do I buy shares of Verona Pharma?

Shares of VRP and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Verona Pharma's stock price today?

One share of VRP stock can currently be purchased for approximately GBX 54.50.

What is Verona Pharma's official website?

The official website for Verona Pharma is http://www.veronapharma.com/.

How can I contact Verona Pharma?

Verona Pharma's mailing address is 3 More London Riverside, LONDON, SE1 2RE, United Kingdom. The company can be reached via phone at +44-20-32834200.

MarketBeat Community Rating for Verona Pharma (LON VRP)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  166 (Vote Outperform)
Underperform Votes:  179 (Vote Underperform)
Total Votes:  345
MarketBeat's community ratings are surveys of what our community members think about Verona Pharma and other stocks. Vote "Outperform" if you believe VRP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel